Barclays PLC Has $2.42 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

Barclays PLC raised its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 22.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 195,553 shares of the company's stock after buying an additional 36,312 shares during the quarter. Barclays PLC owned 0.13% of Wave Life Sciences worth $2,418,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in WVE. Kraematon Investment Advisors Inc. grew its holdings in shares of Wave Life Sciences by 24.3% during the fourth quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company's stock valued at $246,000 after buying an additional 3,885 shares in the last quarter. SG Americas Securities LLC boosted its position in Wave Life Sciences by 46.1% during the 4th quarter. SG Americas Securities LLC now owns 53,419 shares of the company's stock worth $661,000 after acquiring an additional 16,856 shares during the period. KBC Group NV purchased a new position in Wave Life Sciences during the 4th quarter valued at about $67,000. Moody Aldrich Partners LLC increased its holdings in shares of Wave Life Sciences by 31.5% in the 4th quarter. Moody Aldrich Partners LLC now owns 398,475 shares of the company's stock valued at $4,929,000 after purchasing an additional 95,413 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Wave Life Sciences by 126.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 54,267 shares of the company's stock worth $671,000 after purchasing an additional 30,276 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the sale, the director now owns 16,115 shares in the company, valued at $157,443.55. The trade was a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Paul Bolno sold 169,025 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the transaction, the chief executive officer now owns 338,351 shares of the company's stock, valued at approximately $3,238,019.07. This represents a 33.31 % decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have weighed in on WVE. Jefferies Financial Group started coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of Wave Life Sciences in a report on Wednesday, March 26th. Wedbush initiated coverage on Wave Life Sciences in a research note on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 target price on the stock. Cantor Fitzgerald assumed coverage on Wave Life Sciences in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 target price on the stock. Finally, StockNews.com raised Wave Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $21.17.

Wave Life Sciences Stock Down 17.1 %

WVE stock traded down $1.32 during mid-day trading on Tuesday, reaching $6.41. 2,790,134 shares of the stock traded hands, compared to its average volume of 1,255,330. The business has a 50-day moving average of $8.02 and a two-hundred day moving average of $11.33. Wave Life Sciences Ltd. has a 52 week low of $4.25 and a 52 week high of $16.74. The firm has a market capitalization of $987.72 million, a PE ratio of -5.77 and a beta of -0.91.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. The firm had revenue of $83.75 million during the quarter, compared to analysts' expectations of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. On average, equities research analysts anticipate that Wave Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.